Nkarta's EBITDA per Share for the
three
months ended in Dec. 2023 was $-0.59.
During the past 3 years, the average EBITDA Per Share Growth Rate was 5.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -105.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Nkarta was 5.30% per year. The lowest was -423.10% per year. And the median was -5.80% per year.
Competitive Comparison
For the Biotechnology subindustry, Nkarta's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nkarta 3-Year EBITDA Growth Rate Distribution
For the Biotechnology industry and Healthcare sector, Nkarta's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Nkarta's 3-Year EBITDA Growth Rate falls into.
Nkarta 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Nkarta 3-Year EBITDA Growth Rate Related Terms
Thank you for viewing the detailed overview of Nkarta's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NKTX has been successfully added to your